Immunome Inc (IMNM) News

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today...

Form 4 - Statement of changes in beneficial ownership of securities

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050...

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today...